Cargando…

Can urinary exosomes act as treatment response markers in prostate cancer?

BACKGROUND: Recently, nanometer sized vesicles (termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Paul J, Welton, Joanne, Staffurth, John, Court, Jacquelyn, Mason, Malcolm D, Tabi, Zsuzsanna, Clayton, Aled
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631476/
https://www.ncbi.nlm.nih.gov/pubmed/19138409
http://dx.doi.org/10.1186/1479-5876-7-4
_version_ 1782163928230395904
author Mitchell, Paul J
Welton, Joanne
Staffurth, John
Court, Jacquelyn
Mason, Malcolm D
Tabi, Zsuzsanna
Clayton, Aled
author_facet Mitchell, Paul J
Welton, Joanne
Staffurth, John
Court, Jacquelyn
Mason, Malcolm D
Tabi, Zsuzsanna
Clayton, Aled
author_sort Mitchell, Paul J
collection PubMed
description BACKGROUND: Recently, nanometer sized vesicles (termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy. METHODS: Ten patients (with locally advanced PCa) provided spot urine specimens at three time points during standard therapy. Patients received 3–6 months neoadjuvant androgen deprivation therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant ADT according to clinical need. Exosomes were purified, and the phenotype compared to exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present in urine were quantified, and expression of prostate markers (PSA and PSMA) and tumour-associated marker 5T4 was examined. RESULTS: The quantity and quality of exosomes present in urine was highly variable, even though we handled all materials freshly and used methods optimized for obtaining highly pure exosomes. There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa specimens, and not detected in healthy donor specimens. There was a clear treatment-related decrease in exosomal prostate markers in 1 (of 8) patient. CONCLUSION: Evaluating urinary-exosomes remains difficult, given the variability of exosomes in urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple markers of malignancy that could provide clinically useful information.
format Text
id pubmed-2631476
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26314762009-01-28 Can urinary exosomes act as treatment response markers in prostate cancer? Mitchell, Paul J Welton, Joanne Staffurth, John Court, Jacquelyn Mason, Malcolm D Tabi, Zsuzsanna Clayton, Aled J Transl Med Research BACKGROUND: Recently, nanometer sized vesicles (termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy. METHODS: Ten patients (with locally advanced PCa) provided spot urine specimens at three time points during standard therapy. Patients received 3–6 months neoadjuvant androgen deprivation therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant ADT according to clinical need. Exosomes were purified, and the phenotype compared to exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present in urine were quantified, and expression of prostate markers (PSA and PSMA) and tumour-associated marker 5T4 was examined. RESULTS: The quantity and quality of exosomes present in urine was highly variable, even though we handled all materials freshly and used methods optimized for obtaining highly pure exosomes. There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa specimens, and not detected in healthy donor specimens. There was a clear treatment-related decrease in exosomal prostate markers in 1 (of 8) patient. CONCLUSION: Evaluating urinary-exosomes remains difficult, given the variability of exosomes in urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple markers of malignancy that could provide clinically useful information. BioMed Central 2009-01-12 /pmc/articles/PMC2631476/ /pubmed/19138409 http://dx.doi.org/10.1186/1479-5876-7-4 Text en Copyright © 2009 Mitchell et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mitchell, Paul J
Welton, Joanne
Staffurth, John
Court, Jacquelyn
Mason, Malcolm D
Tabi, Zsuzsanna
Clayton, Aled
Can urinary exosomes act as treatment response markers in prostate cancer?
title Can urinary exosomes act as treatment response markers in prostate cancer?
title_full Can urinary exosomes act as treatment response markers in prostate cancer?
title_fullStr Can urinary exosomes act as treatment response markers in prostate cancer?
title_full_unstemmed Can urinary exosomes act as treatment response markers in prostate cancer?
title_short Can urinary exosomes act as treatment response markers in prostate cancer?
title_sort can urinary exosomes act as treatment response markers in prostate cancer?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2631476/
https://www.ncbi.nlm.nih.gov/pubmed/19138409
http://dx.doi.org/10.1186/1479-5876-7-4
work_keys_str_mv AT mitchellpaulj canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT weltonjoanne canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT staffurthjohn canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT courtjacquelyn canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT masonmalcolmd canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT tabizsuzsanna canurinaryexosomesactastreatmentresponsemarkersinprostatecancer
AT claytonaled canurinaryexosomesactastreatmentresponsemarkersinprostatecancer